As increases in IL8 protein levels after treatment with paclitaxel-derived supernatants were greatest in all three breast cancer cell lines (Figure 2b), we postulated that blockade of IL8 or its receptor would diminish the autocrine forward-feedback loop and CSC development. Here, CXCL8 is linked to breast cancer.